Followers | 74 |
Posts | 7298 |
Boards Moderated | 0 |
Alias Born | 09/09/2009 |
Wednesday, March 17, 2021 1:51:03 PM
1. The CEO didn't just offer shares to shareholders, he erased half of what he has lent the company with shares at .05. Meaning if ALRT fails, his $10,000,000 worth of shares at .05 are worthless and his other $10,000,000+ in loans to the company will not get paid back. His success is directly linked to shareholders.
2. Take a look at this PR from 9-18-2019 https://www.globenewswire.com/news-release/2019/09/18/1917335/0/en/ALR-Technologies-to-Integrate-with-CGM-Platforms.html ALRT was being adapted for CGM use which is most certainly the future.
There is speculation about the apple watch reading glucose in the future but that would never be medically reliable, also there are implantable devices such as Eversense XL, but even at the current 6 month use it is not realistic. It leaves scars and requires minor surgery to plant, and yu still have to wear an attachable reader to it. So its basically a CGM that requires biannual surgery.
3. Test strips and glucometers are still used all over the world, including the USA. ALRT offers one of the three most accurate meters on the market with test strips and their platform for a cost cheaper then most supplies alone. It saves money while providing better care.
4. Widescale global success is not needed, if things take off in Singapore or another market/deal is announced we would see a substantial gain in share price based on the low float and share structure. I've broken down the math many times before, but lets just say they make $10 a month from 100k of the 600k+ Singapore diabetics. That is $1,000,000 a month in earnings for a $0.05 stock.
5. The ALRT platform can be adapted to any technology, meters, CGMS, or anything else invented will still need predictive A1C, insulin dose adjustments, and the other benefits ALRT offers.
You have to make the decision if the opportunity cost or risk outweighs the reward. But I hope to see you around in the future. GL
Recent ALRTF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 12:53:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/28/2023 08:49:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 09:15:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM